Dash Protocol for Major Depressive Disorder (MDD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
TMS of South Tampa, Tampa, FL
Major Depressive Disorder (MDD)+3 More
repetitive Transcranial Magnetic Stimulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the comfort of the NeuroStar® Advanced Therapy System regular prescribed TMS protocol versus a feature that alters the pulse magnitude that could provide a more comfortable treatment.

Eligible Conditions

  • Major Depressive Disorder (MDD)

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 10 days

10 days
Evaluate comfort of TMS treatment
5 days
Ability to reach prescribed treatment intensity

Trial Safety

Trial Design

2 Treatment Groups

Dash Protocol
1 of 2
Modified Dash protocol with the SoftStart feature enabled
1 of 2
Active Control

40 Total Participants · 2 Treatment Groups

Primary Treatment: Dash Protocol · No Placebo Group · N/A

Dash Protocol
Device
ActiveComparator Group · 1 Intervention: repetitive Transcranial Magnetic Stimulation · Intervention Types: Device
Modified Dash protocol with the SoftStart feature enabled
Device
ActiveComparator Group · 1 Intervention: repetitive Transcranial Magnetic Stimulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 days
Closest Location: TMS of South Tampa · Tampa, FL
Photo of Tampa 1Photo of Tampa 2Photo of Tampa 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Major Depressive Disorder (MDD)
0 CompletedClinical Trials

Who is running the clinical trial?

NeuroneticsLead Sponsor
22 Previous Clinical Trials
7,595 Total Patients Enrolled
8 Trials studying Major Depressive Disorder (MDD)
7,376 Patients Enrolled for Major Depressive Disorder (MDD)
Steve A Erickson, BSStudy DirectorNeuronetics

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects were asked to consent to receive TMS Therapy to treat MDD with their physician independent of potential participation in this study.
You have provided written consent to participate in the study.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.